Breast cancer · 19 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
AC-THP (Docetaxel, Phesgo) Variant #01 | ERBB2 | R 111 482 | 21d | — | — | ~4 | ~R 172 395 indirect | — |
ddAC-THP (Paclitaxel, Phesgo) Variant #01 | ERBB2 | R 108 125 | 21d | — | — | ~4 | ~R 168 703 indirect | — |
FEC-THP (Docetaxel) Variant #03 | ERBB2 | R 85 709 | 21d | — | — | ~17 | ~R 512 485 PFS proxy · indirect | 1 |
AC-THP (Docetaxel) Variant #01 | ERBB2 | R 81 799 | 21d | — | — | ~17 | ~R 506 586 PFS proxy · indirect | 1 |
ddAC-THP (Paclitaxel) Variant #01 | ERBB2 | R 80 714 | 21d | — | — | ~17 | ~R 505 165 PFS proxy · indirect | 1 |
Neratinib and Paclitaxel, then ddAC Variant #01 | ERBB2 | R 60 624 | 21d | — | — | ~4 | ~R 242 497 indirect | — |
Neratinib and Paclitaxel, then AC Variant #01 | ERBB2 | R 60 624 | 21d | — | — | ~4 | ~R 242 497 indirect | — |
AC-THL (Paclitaxel) Variant #01 | ERBB2 | R 58 935 | 28d | — | — | ~4 | ~R 160 759 indirect | — |
AC-TL (Paclitaxel) Variant #01 | ERBB2 | R 34 004 | 28d | — | — | ~4 | ~R 136 015 indirect | — |
TH-FEC and H (Paclitaxel) Variant #01 | ERBB2 | R 31 871 | 21d | — | — | ~7 | ~R 127 483 indirect | — |
TH-ddAC (Paclitaxel) Variant #01 | ERBB2 | R 30 724 | 21d | — | — | ~4 | ~R 66 660 indirect | — |
TH-AC (Paclitaxel) Variant #01 | ERBB2 | R 30 724 | 21d | — | — | ~4 | ~R 66 660 indirect | — |
ECH-TH (Docetaxel) Variant #01 | ERBB2 | R 23 993 | 21d | — | — | ~4 | ~R 63 168 indirect | — |
EC-TH (Docetaxel) Variant #01 | ERBB2 | R 19 922 | 21d | — | — | ~17 | ~R 109 568 PFS proxy · indirect | 1 |
FEC-TH (Paclitaxel) Variant #01 | ERBB2 | R 18 917 | 21d | — | — | ~17 | ~R 105 449 PFS proxy · indirect | 1 |
TH-FEC and H (Docetaxel) Variant #01 | ERBB2 | R 18 329 | 21d | — | — | ~7 | ~R 59 258 indirect | — |
AC-TH (Paclitaxel) Variant #01 | ERBB2 | R 16 640 | 21d | — | — | ~17 | ~R 99 363 PFS proxy · indirect | 3 |
TH-FEC and H (Docetaxel, SC Trastuzumab) Variant #01 Partial | ERBB2 | R 4 270 | 21d | — | — | ~8 | ~R 17 082 indirect | — |
T-FEC Variant #01 | ERBB2 | R 3 122 | 21d | — | — | ~12 | ~R 17 385 indirect | — |
19 of 19 regimens shown